EGFR and glioblastoma: In glioblastoma, nuclear IGFBP2 leads to aberrant EGFR and STAT3 signaling in vitro, and RCAS-mediated IGFBP2 expression increased glioblastoma formation and progression in vivo in a mouse model, which was reversed when IGFBP2 expression was inactivated [13].